N- ((4- cyano- 2- (trifluoromethyl)phenyl)methyl)- 3- ((4- methyl- 6- (methylamino)- 1,3,5- triazin- 2- yl)amino)cyclohexanecarboxamide

inhibits soluble epoxide hydrolase; structure in first source

Also Known As:

GSK2256294

Networked: 6 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Cyclohexylamines: 33
    - N-((4-cyano-2-(trifluoromethyl)phenyl)methyl)-3-((4-methyl-6-(methylamino)-1,3,5-triazin-2-yl)amino)cyclohexanecarboxamide: 6
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Alicyclic Hydrocarbons: 1
      - Cycloparaffins: 6
        Cyclohexanes: 3
        Cyclohexylamines: 33
        N-((4-cyano-2-(trifluoromethyl)phenyl)methyl)-3-((4-methyl-6-(methylamino)-1,3,5-triazin-2-yl)amino)cyclohexanecarboxamide: 6
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Triazines: 306
    - N-((4-cyano-2-(trifluoromethyl)phenyl)methyl)-3-((4-methyl-6-(methylamino)-1,3,5-triazin-2-yl)amino)cyclohexanecarboxamide: 6

Experts

1.	Marino, Joseph P: 2 articles (01/2021 - 04/2013)
2.	Hoang, Bao: 2 articles (01/2019 - 04/2013)
3.	Alkayed, Nabil J: 1 article (01/2022)
4.	Allen, Elyse: 1 article (01/2022)
5.	Cetas, Justin: 1 article (01/2022)
6.	Martini, Ross P: 1 article (01/2022)
7.	Siler, Dominic: 1 article (01/2022)
8.	Treggiari, Miriam M: 1 article (01/2022)
9.	Belyanskaya, Svetlana: 1 article (01/2021)
10.	Brown, Nancy J: 1 article (01/2021)

Related Diseases

1.	Inflammation (Inflammations) 01/01/2022 - "We conducted a double-blind, placebo-controlled, phase Ib randomized trial of GSK2256294, a pharmacologic inhibitor of sEH, to evaluate the safety profile and to assess biomarkers of neurovascular inflammation in patients with aneurysmal SAH. "
2.	Chronic Obstructive Pulmonary Disease (COPD) 01/01/2021 - "The 1,3-cycloalkyl chemotype led to the discovery of a clinical candidate (GSK2256294) for COPD." 03/01/2017 - "GSK2256294 attenuates smoking-related EET-mediated endothelial dysfunction, suggesting potential therapeutic benefits in patients with COPD. " 03/01/2017 - "We tested the hypothesis that endothelium-derived epoxyeicosatrienoic acid (EET)-mediated endothelial function is impaired in patients with COPD and that a novel soluble epoxide hydrolase inhibitor, GSK2256294, attenuates EET-mediated endothelial dysfunction in human resistance vessels both in vitro and in vivo. "
3.	Overweight 03/01/2017 - "The effects of GSK2256294 on EET-mediated vasodilation in human resistance arteries were assessed in vitro and in vivo in a phase I clinical trial in healthy overweight smokers. "
4.	Critical Illness (Critically Ill) 01/01/2022 - "GSK2256294 administration was safe and well tolerated in critically ill patients with SAH, producing an increase in serum EETs and the EET-to-DHET ratio. "
5.	Rupture 01/01/2022 - "Patients were randomly assigned to receive 10 mg of GSK2256294 or a placebo treatment once daily for 10 days, beginning within 72 hours after aneurysm rupture. "

Related Drugs and Biologics

1.	Biomarkers (Surrogate Marker)
2.	Epoxide Hydrolases
3.	F2-Isoprostanes (F2 Isoprostanes)
4.	Interleukin-10 (Interleukin 10)
5.	Interleukin-4 (Interleukin 4)
6.	Interleukin-2 (IL2)
7.	Acids
8.	N- ((4- bromo- 2- ((trifluoromethyl)oxy)phenyl)methyl)- 1- (4- methyl- 6- (methylamino)- 1,3,5- triazin- 2- yl)- 4- piperidinecarboxamide